Mechanomeric Oncotherapy
John
cancer cells but not to cells of their parent (or other normal) types
can be developed empirically[1], for the individualized oncotherapies
or idiotherapies necessitated by the individualized nature of cancers.
Cancer cells are mutated cells, with at least one and usually multiple
abnormal biopolymers (biological mechanomers, mostly DNAs, messenger
RNAs and proteins), and the differences between such biopolymers and
their normal parent biopolymers will allow the empirical development
of mechanomers which are toxic to such cells only (e.g., lethal
enzymes activated by complexing with such abnormal biopolymers only).
At its simplest, such development will take the form of parallel
matricial empirical mechanomeric development[1]: overlaying a set of
parallel identical replicated random mechanomer matrices with,
respectively, a culture of the cancer cells in question, perhaps a
culture of the parent cell-type of that cancer, and cultures of as
many other (normal) cell types generated and cultured from the patient
as practicable; observing for regions where on the first matrix the
cancer cells die but on the others none do; extracting the random
mechanomers from those regions from yet another parallel matrix; re-
matriciating the mechanomers from each such region using different
media to separate them; and repeating, until a set of individualized
antineoplastic or oncotherapeutic mechanomers is developed.
It is unlikely that even with the use of multiple oncotherapeutic
mechanomers that all the cells of a cancer will be killed, and indeed
some if not most cancers more or less steadily mutate, so the
mechanomeric oncotherapies of such cancers will therefore involve not
only multiple mechanomers but also one or more extra passes or rounds
of such multiplex therapy, as the cancer reoccurs to be re-sampled and
a new set of oncotheraputic mechanomers developed to deal with it,
with the majority of such cells destroyed by each pass, and a
genetically-different minority left (if any) to begin again (note that
even if not directly destroyed, the cells of such cancer held in check
long enough should become ever more mutated, function ever more
poorly, with ever greater numbers of its cells being fatally mutated,
or exhibiting mutated biopolymers detectable and those cells therefore
destroyed by the immune system, in "neoplastic burnout").
[1] John Kennard, "Empirical Mechanomeric Development", Usenet post,
crossposted to the Usenet newsgroups sci.bio.technology, sci.life-
extension and sci.research, on February 8, 2010,
Message-ID:<dc9ea25d-2a97-4433-
b12b-9ba...@c5g2000vbh.googlegroups.com>
viewable at
http://groups.google.com/group/sci.bio.technology/browse_thread/thread/6eb4ad05137621be#
and added on April 10, 2010, to the blog jdkabc.blogspot.com and
viewable at
http://jdkabc.blogspot.com/2010/04/empirical-mechanomeric-development.html
Keywords: biopolymers, cancer, idiotherapy, matricial empirical
mechanomeric development, mechanomeric oncotherapy, mechanomers